Johnson County Clin Trials (JCCT), a leader in clinical research for 20 years, proudly announces the appointment of Dan White as its new Chief Executive Officer. This leadership transition comes as co-founders and Co-CEOs Nathan Arthur and Mazen Zari step into advisory roles, following two decades of visionary leadership.
Dan has over 30 years of experience in the clinical research industry, including key roles in business development and operational leadership. As CEO, he will focus on driving strategic growth, operational excellence, and the continued development of JCCT’s site network and therapeutic expertise.
“JCCT has a strong foundation and an exceptional team,” said Dan White, CEO. “I’m honored to lead the organization into this exciting new chapter, expanding our network and therapeutic coverage while deepening our impact in clinical research.”
JCCT conducts clinical trials across a broad spectrum of therapeutic areas, including vaccines, nephrology, and cardiometabolic diseases—backed by deep expertise in first‑in‑human studies, allergy, cardiovascular, endocrine/metabolism, infectious diseases, and more. With the recent addition of a site in Kansas City, MO, and new affiliations with leading physician groups, the company is well-positioned for continued growth and expanded impact in the clinical research industry.
“We’ve spent the last 20 years building JCCT into a trusted research partner,” said Nathan Arthur, Co-Founder. “Dan brings the leadership and experience needed to take it to the next level.”
“Dan shares our commitment to science, innovation, and people,” added Mazen Zari, Co-Founder. “We are confident in his ability to guide JCCT’s continued growth and success.”
“JCCT’s future is bright,” said Board Member Karen Winterhof. “Dan’s leadership, paired with the co-founders’ continued strategic involvement, ensures continuity with fresh energy and direction.”
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!